JP2006503095A - 反応性関節炎または滑液包炎の治療法 - Google Patents

反応性関節炎または滑液包炎の治療法 Download PDF

Info

Publication number
JP2006503095A
JP2006503095A JP2004545314A JP2004545314A JP2006503095A JP 2006503095 A JP2006503095 A JP 2006503095A JP 2004545314 A JP2004545314 A JP 2004545314A JP 2004545314 A JP2004545314 A JP 2004545314A JP 2006503095 A JP2006503095 A JP 2006503095A
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
dose
metronidazole
hydrochloride
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004545314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006503095A5 (enExample
Inventor
アーネスト・エル．・ボナー
ロバート・ヒネス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2006503095A publication Critical patent/JP2006503095A/ja
Publication of JP2006503095A5 publication Critical patent/JP2006503095A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2004545314A 2002-10-15 2003-10-14 反応性関節炎または滑液包炎の治療法 Pending JP2006503095A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/271,117 US6765000B2 (en) 1999-03-17 2002-10-15 Treatment for reactive arthritis or bursitis
PCT/US2003/032653 WO2004034987A2 (en) 2002-10-15 2003-10-14 Treatment for reactive arthritis or bursitis

Publications (2)

Publication Number Publication Date
JP2006503095A true JP2006503095A (ja) 2006-01-26
JP2006503095A5 JP2006503095A5 (enExample) 2006-12-07

Family

ID=32106409

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004545314A Pending JP2006503095A (ja) 2002-10-15 2003-10-14 反応性関節炎または滑液包炎の治療法

Country Status (10)

Country Link
US (3) US6765000B2 (enExample)
EP (1) EP1558266A4 (enExample)
JP (1) JP2006503095A (enExample)
KR (1) KR20050083762A (enExample)
CN (1) CN100584335C (enExample)
AU (2) AU2003284231A1 (enExample)
CA (1) CA2502397A1 (enExample)
CH (1) CH696629A5 (enExample)
MX (1) MXPA05003930A (enExample)
WO (1) WO2004034987A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017525719A (ja) * 2014-08-18 2017-09-07 シルべストリ、 ファブリツィオ デ 関節リウマチの治療における１つの丸剤・錠剤・カプセル剤でのミノサイクリン、アシクログアノシン、アトルバスタチンおよびビタミンｄの使用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6765000B2 (en) * 1999-03-17 2004-07-20 Bonner Jr Ernest L Treatment for reactive arthritis or bursitis
US7691831B2 (en) * 1999-03-17 2010-04-06 Ernest L. Bonner, Jr. Pharmaceutical combination and method for treatment of reactive arthritis or bursitis
US7884090B2 (en) * 1999-03-17 2011-02-08 Ernest L. Bonner, Jr. Compositions and methods for the treatment of arthritis
US20050137181A1 (en) * 1999-03-17 2005-06-23 Bonner Ernest L. Method for treatment of reactive arthritis or bursitis
CN1293883C (zh) * 2004-05-21 2007-01-10 邹宏 一种美容修护液及其制备方法
US7312343B2 (en) * 2004-06-02 2007-12-25 Hoffmann-La Roche Inc. Synthesis of α-amino-β-alkoxy-carboxylic acid esters
EP1861110B1 (en) * 2004-12-17 2014-03-26 Venus Remedies Limited Antibiotic combinations for providing total solution to the treatment of infections
WO2006096555A1 (en) * 2005-03-04 2006-09-14 Women And Infants Hospital Of Ri, Inc. Compositions and methods for cancer treatment
JP5395052B2 (ja) * 2007-03-23 2014-01-22 モレキュラー リサーチ センター インコーポレイテッド 炎症を処置するための組成物および方法
US9675727B2 (en) * 2007-04-10 2017-06-13 Mediwise Pty Ltd. Method and device for treating bursitis
EP2018864A1 (en) * 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
KR102806503B1 (ko) * 2021-07-29 2025-05-16 가톨릭대학교 산학협력단 렘데시비르와 면역조절제 병용투여법을 통한 자가면역류마티스 질환 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09136842A (ja) * 1995-11-14 1997-05-27 Shigemasa Sawada 抗慢性関節リウマチ剤
US6197776B1 (en) * 1999-03-17 2001-03-06 Ernest L. Bonner, Jr. Method for treatment of reactive arthritis or bursitis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2946801A (en) 1957-06-05 1960-07-26 Standard Oil Co Production of pyridine carboxylic acids
US3148212A (en) 1961-12-22 1964-09-08 American Cyanamid Co Reductive alkylation process
USRE26253E (en) 1963-05-17 1967-08-15 And z-alkylamino-g-deoxytetracycline
US4177796A (en) 1977-08-22 1979-12-11 Franco Vila Jose J Magnetic thermal vibrational device for the treatment of arthritis and the like
US4521411A (en) 1983-11-04 1985-06-04 Theodora Koloff Analgesic composition
US5728680A (en) * 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
US5523297A (en) 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
FI954911A0 (fi) * 1993-04-16 1995-10-16 Mccormick & Co Inc Kapselointikoostumukset
GB9425487D0 (en) 1994-12-16 1995-02-15 Res Inst Osteoarthritis treatment
US6093414A (en) * 1997-08-11 2000-07-25 Christopher C. Capelli Silver-based antimicrobial compositions
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5952367A (en) 1997-04-25 1999-09-14 Pak; Kyoungsik Method of treating pain cause by bursitis tendinitis arthritis
US6416779B1 (en) * 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US6087382A (en) * 1999-03-17 2000-07-11 Bonner, Jr.; Ernest L. Method for treatment of reactive arthritis or bursitis
US20050137181A1 (en) 1999-03-17 2005-06-23 Bonner Ernest L. Method for treatment of reactive arthritis or bursitis
US6765000B2 (en) 1999-03-17 2004-07-20 Bonner Jr Ernest L Treatment for reactive arthritis or bursitis
US7884090B2 (en) * 1999-03-17 2011-02-08 Ernest L. Bonner, Jr. Compositions and methods for the treatment of arthritis
US20040015367A1 (en) * 2000-10-30 2004-01-22 Nicastro Cherisse M. Business asset management system using virtual areas
EP1359921A4 (en) 2001-01-19 2006-09-06 Newbiotics Inc METHODS RELATING TO THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
US20040024624A1 (en) * 2002-07-31 2004-02-05 Ciscon Lawrence A. Method and system for leveraging functional knowledge using a requirement and space planning tool in an engineering project

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09136842A (ja) * 1995-11-14 1997-05-27 Shigemasa Sawada 抗慢性関節リウマチ剤
US6197776B1 (en) * 1999-03-17 2001-03-06 Ernest L. Bonner, Jr. Method for treatment of reactive arthritis or bursitis
WO2002003920A2 (en) * 2000-07-10 2002-01-17 Bonner Ernest L Method for treatment of reactive arthritis or bursitis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017525719A (ja) * 2014-08-18 2017-09-07 シルべストリ、 ファブリツィオ デ 関節リウマチの治療における１つの丸剤・錠剤・カプセル剤でのミノサイクリン、アシクログアノシン、アトルバスタチンおよびビタミンｄの使用

Also Published As

Publication number Publication date
US20050176690A1 (en) 2005-08-11
MXPA05003930A (es) 2005-06-17
WO2004034987A3 (en) 2004-07-15
CN1729006A (zh) 2006-02-01
WO2004034987A2 (en) 2004-04-29
EP1558266A4 (en) 2007-12-26
CA2502397A1 (en) 2004-04-29
US20050059640A1 (en) 2005-03-17
EP1558266A2 (en) 2005-08-03
AU2009238327A1 (en) 2009-12-10
KR20050083762A (ko) 2005-08-26
CH696629A5 (de) 2007-08-31
CN100584335C (zh) 2010-01-27
AU2003284231A1 (en) 2004-05-04
US20030055022A1 (en) 2003-03-20
US7053073B2 (en) 2006-05-30
US6765000B2 (en) 2004-07-20

Similar Documents

Publication Publication Date Title
US6465473B1 (en) Method for treatment of reactive arthritis or bursitis
AU2009238327A1 (en) Treatment for reactive arthritis or bursitis
Raborn et al. Oral acyclovir and herpes labialis: a randomized, double-blind, placebo-controlled study
US6197776B1 (en) Method for treatment of reactive arthritis or bursitis
AU2001280519A1 (en) Method for treatment of reactive arthritis or bursitis
TW202332451A (zh) 手部溼疹之治療
US20050137181A1 (en) Method for treatment of reactive arthritis or bursitis
US7691831B2 (en) Pharmaceutical combination and method for treatment of reactive arthritis or bursitis
WO2016101324A1 (zh) 含有酶的天然组合物及其在制药中的应用
US4751236A (en) Method for treating genital herpes
US10080761B2 (en) Method for treating recurring skin and mucous membrane diseases caused by HSV-1 and HSV-2
Nikitina et al. Infectious complications as predictors of adverse outcome in a patient with systemic lupus erythematosus (clinical case)
CZ34480U1 (cs) Přípravek s účinky proti lupénce
UA7302U (en) Method for complex treatment of lambliasis

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20051107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100901

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20100901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101101

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20110412

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20110802

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A072

Effective date: 20111206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111220